Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00331786 · ClinicalTrials.gov registry record · Phase 1
Nitric Oxide-Releasing Acetylsalicyclic Acid in Preventing Colorectal Cancer in Patients at High Risk of Colorectal Cancer
A Phase 1 study, sponsored by Stony Brook University.
- Completed
- Registry status
- Phase 1
- Development phase
- 240
- Enrollment target
NCT00331786 is a Phase 1 study that has completed, run by Stony Brook University. The registered enrollment target is 240 participants.
The verdict
NCT00331786, a Phase 1 study, has completed, sponsored by Stony Brook University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 240 participants
- Enrollment target
Study Summary
RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming, growing, or coming back. The use of nitric oxide-releasing acetylsalicyclic acid may prevent colorectal cancer. PURPOSE: This randomized phase I trial is studying the side effects and best dose of nitric oxide-releasing acetylsalicyclic acid in preventing colorectal cancer in patients at high risk of colorectal cancer.
Interventions
- OTHER laboratory biomarker analysis
- PROCEDURE biopsy
- DRUG nitric oxide-releasing acetylsalicylic acid derivative
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 240 participants |
| Start Date | 2006-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00331786
The ClinicalTrials.gov registry entry for NCT00331786 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 240 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stony Brook University, which has 127 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which laboratory biomarker analysis is the first listed.
NCT00331786 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00331786 about?
NCT00331786 is a clinical study titled "Nitric Oxide-Releasing Acetylsalicyclic Acid in Preventing Colorectal Cancer in Patients at High Risk of Colorectal Cancer". RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming, growing, or coming back. The use of nitric oxide-releasing acetylsalicyclic acid may prevent colorectal cancer. PURPOSE: This randomized phase I trial is studying the side effects and best dose of nitric oxide-relea...
What is the current status of trial NCT00331786?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 240 participants. The study started on 2006-07.
What interventions are being tested in trial NCT00331786?
The interventions under investigation include: laboratory biomarker analysis (OTHER), biopsy (PROCEDURE), nitric oxide-releasing acetylsalicylic acid derivative (DRUG).
Who is sponsoring clinical trial NCT00331786?
This trial is sponsored by Stony Brook University, which has 127 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.